RSS

Category Archives: Stocks

Market Research of Keppel DC REIT

Image result for Keppel DC REIT

Keppel DC REIT (KDCREIT) reported its 3Q17 results which met our expectations. Gross revenue and NPI jumped 56.6% and 42.1% YoY to S$35.5m and S$32.3m, respectively.

This was largely driven by the acquisitions of the 90% interest of KDC SGP 3, Milan DC, Cardiff DC and to a smaller extent B10 DC in Dublin (half a month of contribution), coupled with higher variable income from KDC SGP 1 due to an increase in recurring revenue.

DPU grew 16.8% YoY to 1.74 S cents. If we make adjustments to account for the impact of the preferential offering exercise and a one-off net property tax refund in 3Q16, KDCREIT’s adjusted DPU would have increased 4.2% YoY.

For 9M17, KDCREIT’s gross revenue spiked up 41.4% to S$102.2m and formed 76.8% of our FY17 forecast. DPU rose 11.2% to 5.37 S cents (adjusted DPU +4.2% to 5.22 S cents) and constituted 74.0% of our full-year projection.

Operationally, KDCREIT’s portfolio occupancy creeped up 0.3 ppt QoQ to 93.4% as there was slight improvement recorded at KDC SGP 1 and Keppel DC Dublin 1.

Pertaining to Singapore’s data centre industry, management highlighted that while there are still some vacancies in the market, it remains upbeat that this space will eventually be absorbed in the foreseeable future given limited upcoming supply and robust demand, especially from the cloud service providers.

Maintain BUY and S$1.39 fair value estimate on KDCREIT.

More Update:Share trading tipsSGX Stock PicksShare Market signals for Singapore stock Market

Venture Corp Share Investment Singapore www.mmfsolutions.sg

Advertisements
 
Leave a comment

Posted by on October 17, 2017 in Stocks

 

Tags: , , , , , , , , , , , , ,

Good Time to Sell or Buy SingPost

  • Boost from 701Search stake sale
  • Sound approach to rationalization
  • FV estimate updated to S$2.93

FY17 PATMI Boosted by One-time Divestment Gain

Singapore-momentum-stocks-SingPost
SPH reported that FY17 PATMI increased 32.0% YoY to S$350m mostly due to a gain of S$150m from a partial divestment of the group’s stake in the regional online classifieds business, and a fair value gain on investment properties of S$57m, which were partially offset by impairment charges of S$96m on the group’s magazine business and printing presses.

Excluding these one-time charges, however, FY17 recurring earnings declined 20% YoY and FY17 operating revenues also declined 8% lower as the core media business continued to suffer the disruption of digital media. The property segment, however, delivered steady results as revenues increased 1% YoY from higher rental income from the group’s retail assets.

We deem this set of results to be mostly within our expectations. A final dividend of 9 S-cents per share has been proposed, bringing total dividends in FY17 to 15 S-cents.

Catch more – Good Time to Buy Keppel Corp

Sound Approach to Rationalizing Media Business

While there is no denying the impact of digital disruption on the group’s core media earnings – which continue to decline over the latest quarter – our view is that the management team’s approach in rationalizing the business is mostly realistic and sound. The group will complete a 10% staff reduction by this calendar year, incurring retrenchment costs of S$13m, and will also invest for new growth in terms of digital, data analytics, radio broadcasts, video and content marketing capabilities. This will also help the group better meet the changing needs of their market.

Since we have upgraded the stock to a buy rating three weeks ago, we note that the price has rebounded but, as we update our valuation model for the latest results and assumptions, our fair value estimate declines to S$2.93 versus S$3.25 previously. We, therefore, downgrade our rating to HOLD on valuation grounds.

More Update: Stocks To Watch and hot stocks picks with Stock trading tips or Share Market Tips

 
Leave a comment

Posted by on October 13, 2017 in Stocks

 

Tags: , , , , , , , , , , , , ,

[Singapore Stock] QT VASCULAR LTD Movements

Currently trading around a penny a share Singapore Stock QT Vascular (QTVLF) is one of the most undervalued biotech/medical stocks I have ever seen! With FDA and EU approval for it’ s coronary products, a new partnership with the World&rsquo s leading medical device company, US sales booming, backed by the government of Singapore with large foreign institutional and insider ownership, received a US Congressional award, revenues projected to skyrocket (already in the millions), debt being slashed about to become cash flow positive with expansion into Europe and Asia ramping up! Crazy undervalued now, the share price is only going to rise!

QT Vascular (QTVLF) is already selling their FDA and European Union approved coronary balloon catheter’ s and other coronary angioplasty products to over 150 Hospitals in the US alone! With US sales BOOMING and projected to skyrocket, that is just the beginning! Read this entire write up and you will be stunned how EXTREMELY UNDERVALUED QT Vascular (QTVLF) is!

All due diligence posted here is verifiable and comes straight from the CEO, the company’ s filings, audited financials, website and official press releases!….

QTVLF ALSO now has full FDA clearance and has begun clinical trials on a NEW revolutionary drug-coated coronary balloon catheter that is less invasive and does not involve placing a permanent implant!

QT Vascular (QTVLF) is a global company engaged in the development and commercialization of innovative devices for the minimally invasive treatment of vascular disease without the use of permanent implants (stents).

Currently moving Near – 0.010 with Moderate Range. Stay Alert with Singapore market Movements

QT Vascular (QTVLF) HIGHLIGHTS

,,,,,,,

1-QTVLF CEO says debt at the end of 2016 was slashed by approximately US$7.8 million from US$19.2 million in 2015 to US$11.4 million. With US sales growing and the new agreement for distribution with the world&rsquo s leading medical device company global giant Medtronics CEO says debt will continue to be taken out through 2017! (Strong Buy Signal!)

2-QTVLF is backed by the Singaporean government who is fast becoming a world leader in promoting life sciences, investing heavily in firms and in the sort of infrastructure that will support the industry through it’ s state-financed biomedical sciences investment fund (BMSIF)

3-QTVLF also backed by other major established and reputable shareholders include Three Arch Partners, a healthcare fund which has internally incubated more than a dozen start-up healthcare companies AND Luminor Pacific Fund 1 is a private equity healthcare-focused fund based in Singapore approved under the Singapore government&rsquo s global investor programme.

4-QTVLF following the AWESOME new 2017 agreement with Medtronic that went into effect March 1st 2017 the company then received an offer for up to $20 MILLION CAPITAL COMMITMENT on favorable terms from US-based New York private investment group GEM GLOBAL. GEM is a USD 3.4 billion investment group having completed 372 transactions in 70 countries. (Strong Buy Signal!)
….

5-QTVLF CEO says they are currently selling their coronary balloon catheter’ s and other coronary angioplasty products to over 150 Hospitals in the United States alone! (Strong Buy Signal!)

6-QTVLF has filed over 40 patents filed worldwide on it’ s coronary balloon catheter’ s and other coronary angioplasty products

7-QTVLF Awards and Recognition: company received a Certificate of Special Congressional Recognition from U.S. Congressman Jerry McNerney

8-QTVLF Awards and Recognition the company subsidiary, TriReme US, was recognized by the City of Pleasanton where it is based for its ongoing contributions to the strength of the economy locally and positive impacts to the quality of life globally

9-QTVLF is the first ever Singapore based biotech medical company to receive approval US Food and Drug Administration (&ldquo FDA&rdquo ) for an interventional medical device developed in Singapore
….

10-QTVLF is heading towards being CASH FLOW POSITIVE, reduced loss from US$53.1 million in FY2015 to US$12.0 million in FY2016, That is phenomenal! With the new distribution agreement with the world&rsquo s leading medical device company, Medtronic complete debt elimination and massive revenue increases will continue! (Strong Buy Signal!)

11-QTVLF CEO says that US sales in 2106 of it’ s coronary products increased a WHOPPING 49% equalling an increased per sales representative efficiency of 114% (Strong Buy Signal!)

12-QTVLF PRODUCTS are in DEMAND, CEO says they working hard to increase production in support of the new distribution agreement.the world&rsquo s leading medical device company, Medtronic. (Strong Buy Signal!)

13-QTVLF CEO says that in 2016 the US remained the companies largest market, accounting for 86.9% of total revenue. Sales to Europe improved during the year. Europe accounted for 5.8% of total revenue with US$620,000 in sales, compared with US$426,000 a year ago. With the new 2017 agreement with the world&rsquo s leading medical device company, Medtronic global and European sales are forecast to substantially increase!

14-QTVLF has obtained the approval from the US Food and Drug Administration (&ldquo FDA&rdquo ) to sell an improved version of it’ s coronary angioplasty product named Chocolate® PTCA known as Chocolate XD® (Strong Buy Signal!)

15-QTVLF ALSO received full approval from the US Food and Drug Administration (&ldquo FDA&rdquo ) to begin the pivotal study of the drug-coated version of it’ s coronary angioplasty product Chocolate® PTA known as Chocolate Touch® . This is only the 4th such device to ever receive such approval by the FDA (Strong Buy Signal!)

Read More – Things Most People Don’t Know About Qt Vascular Target Price

16-QTVLF on July 31, 2017, company announced it has started enrollment in its US Food and Drug Administration (&ldquo FDA&rdquo ) pivotal clinical study. The study will evaluate the Company’ s drug-coated balloon (” DCB” ), the Chocolate Touch® , for use in superficial femoral and popliteal arteries with the intention of obtaining a US regulatory approval. The co-principal investigators of the study are Dr. Mehdi Shishehbor of the University Hospitals of Cleveland and Professor Thomas Zeller of the Heart Center in Bad Krozingen, Germany.

17-QTVLF has generated awesome positive clinical data It’ s coronary angioplasty product Chocolate PTA achieved a 0% failure rate during a human trial study on 22 patients in Germany and New Zealand for one year, and subsequent follow-ups showed no complications. Data from the first 350 patients of a separate human trial study of the Chocolate PTA in the United States showed high rates of treatment success and limb preservation. (Strong Buy Signal!)CEO says ” We are delighted with the angiographic results of Chocolate Heart&trade showing maintenance of patency at two years,” stated Eitan Konstantino, PhD, CEO of QT Vascular. ” Those patients are doing well without a stent in their heart and this is exactly what we are here for.” (Strong Buy Signal!)

CEO also said ” in keeping with our commitment to proving the clinical value of our technology, we announced the 12 month outcomes of the Chocolate Heart® First-in-Human Study, the final results of the US registry of Chocolate® PTA known as Chocolate BAR, and the final results of the Chocolate Touch® First-in-Human trial known as ENDURE. The results of all of these studies added significantly to the body of evidence supporting the unique benefits of the Chocolate® platform” (Strong Buy Signal!)

Read More – Advanced Guide to Qt Vascular Target Price

18-QTVLF In Europe has ALSO obtained CE mark clearance for Chocolate Heart® , the coronary drug-coated balloon (Strong Buy Signal!)

19-QTVLF new cutting-edge proprietary technologies: CEO on the NEW revolutionary drug-coated coronary products ” The area of peripheral arterial disease remains very much under-treated. While stents are used to treat some of these patients, there is a growing preference for therapies such as drug-coated balloons that do not involve placing a permanent implant. Sales of drug-coated balloons are estimated to have surpassed US$300 million in 2016 in the US market and the global market will surpass US$1 billion in sales by 20202. QT Vascular is well positioned to benefit from the increased adoption of drug-coated balloons. Chocolate Touch® has received full FDA clearance to begin the pivotal trial. Upon approval, this would make Chocolate Touch® only the 4th such device to be approved in the US.

The final results of Chocolate Touch® &rsquo s first-in-human trials are similar to the best-in-class devices. The Company&rsquo s recently announced a distribution agreement with Medtronic, along with the recent launch of the Group&rsquo s latest generation coronary device, Chocolate XD® , bode well for supporting our growth in FY2017.” (Strong Buy Signal!)

Read More –  Signs You Work With Qt Vascular Target Price

20-QTVLF while conducting most of it’ s business in the US it is strategically located in Singapore, a hub of Asia and have access to the markets in the PRC and Japan through distribution agreements. The business-friendly environment in Singapore will allow the use Singapore as the Asian hub for the companies Asian focused marketing activities, revenues in Asia which are forecast to grow significantly with the companies new outreach into mainland ChinaThe companies top markets include the USA and growing medical device markets, especially in Europe, China, Japan and other parts of Asia. CEO says ” Our products are focused on the treatment of cardiovascular diseases, which are the number one cause of death globally, and half of all such cases are estimated to occur in Asia”

21-QTVLF expansion into mainland China, a distribution agreement with Weihai Weigao Medical Devices, Ltd. for the distribution of our peripheral products, the GliderXtreme PTA, GliderfleX PTA and Chocolate PTA coronary products in the People&rsquo s Republic of China.Weihai Weigao Medical Devices is a leading supplier of medical devices in China.Weihai Weigao has an extensive sales network comprising 25 sales offices, 38 customer liaison centers, and 170 municipal representative offices. As at the date of this report, Weihai Weigao has a total customer base of 5,159 (including 3,090 hospitals, 414 blood stations, 611 other medical units and 1,044 distributors). (Strong Buy Signal!)

22-QTVLF expansion into mainland China, QTVLF ALSO recently announced that it has signed an agreement with the Administrative Committee of Shijiazhuang High-Tech Industry Development Zone and China VAST Industrial Urban Development Company Limited to explore opportunities for cooperation in areas including, inter alia, project development, biotechnology sharing, talent exchange and fundraising. SJZ High-Tech Zone and China VAST shall provide the land for research and development within SJZ High-Tech Zone, and assist QT Vascular in obtaining capital and other resources. SJZ High-Tech Zone shall assist to present QT Vascular’ s biotechnology and its products to companies in SJZ High-Tech Zone, to explore opportunities such as joint research and development programs and the distribution of QT Vascular’ s products in China.

23-QTVLF already has a distribution agreement with Japan-based Century Medical Inc for the distribution of QTVLF products in Japan. Century Medical is one of the largest independent medical device distributors in Japan. With over 40 years experience marketing medical devices in Japan.

Read More- Greatest Moments in Qt Vascular Target Price History

24-QTVLF Top Management Executive Vice President Ms. Pizarro spent 10 years at Boston Scientific, Neurovascular Division, where she led neurovascular minimally invasive device research (intracranial implantable devices) and development projects from concept to commercialization. Prior to joining TriReme, Ms. Pizarro was the Director of Research and Development at AngioScore Inc., where she led the development of cardiovascular and peripheral devices QT Vascular (QTVLF) Company Description

QT Vascular Ltd., together with its subsidiaries, designs, assembles and distributes therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The company offers coronary products, including Chocolate percutaneous transluminal coronary angioplasty (PTCA) balloon catheter to reduce vessel trauma by providing balloon inflation and Glider PTCA for the treatment of various complex lesions.
It also provides Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of blocked arteries Chocolate Touch, a drug-coated balloon catheter GliderfleX PTA for treating distal peripheral vessels and GliderXtreme PTA balloon catheter that targets complex lesions in the distal peripheral vasculature.

The company sells its products through its direct sales team. It has operations in the United States, Singapore, Japan, Europe, China, Australia, and Hong Kong. QT Vascular Ltd. was incorporated in 2013 and is based in Singapore.

Summary

Now is the time to buy shares of QT Vascular Ltd. (QTVLF), trading near historic lows and under the radar this award-winning biotech medical company is about to become cash flow positive. With millions in revenues and debt being slashed, new funding now being offered on favorable terms, like the $20 million from Global Emerging Markets, the US-based investment group as institutions discover the value that QT Vascular Ltd. (QTVLF) presents!

Partnering up with the the world’s leading medical device company global giant Medtronic, US sales setting NEW RECORDS and BOOMING and with the company making significant headway into the Asian markets especially China you can see how EXTREMELY UNDERVALUED this biotech is trading around a penny!

When you factor in the support it receives from the country of Singapore through it’ s state-financed biomedical sciences investment fund and the huge percentage of shares that insiders and foreign institutions own it easily stands out to me as one of America’ s MOST UNDERVALUED stocks!

I do not know of any biotech stock or otherwise, that is trading around a penny that has been recognized and received an award from the US Congress and from a US City and that also has multiple products ALREADY APPROVED by both the FDA and the EU. With it’ s products already being commercialized and new cutting edge FDA trials approved and happening the share price is only going to rise from this point.

 
Leave a comment

Posted by on October 11, 2017 in Stocks

 

Tags: , , , , , , , ,

Singapore Stock City Developments Limited Update

  • Possible offer for M&C
  • Cash offer of 552.5 pence per share
  • Likely accretive if successful

Possible Cash Offer of 552.5 Pence Per M&C Share

Singapore Stock City Developments Limited Update

CDL announced that they have reached an agreement with the independent directors of Millennium & Copthorne Hotels PLC (M&C) on the price at which these directors will recommend a possible cash offer by CDL for all the outstanding M&C ordinary shares that CDL does not already own. As at 9 Oct 2017, CDL indirectly owns 65.2% of the shares of M&C.

The proposed cash consideration comprises a cash amount of 545 pence per M&C share and a special dividend of 7.5 pence per share which will be payable upon the offer becoming unconditional. This represents a 22.0% premium to the VWAP of 452.7 pence per share over the period of one month before 6 Oct 2017, and also a 21.4% premium to the closing share price of 455.0 pence on 6 Oct 2017.

No Certainty That a Formal Offer Will be Made

We highlight that there is no certainty a formal offer will be made, and discussions on the other terms and conditions of the proposed offer are still ongoing. If successful, we see this as a positive development for CDL which will almost certainly be accretive. Given green shoots in the global economy, the outlook for hospitality assets is broadly turning positive.

In addition, CDL already indirectly owns a substantial stake in M&C, and intimately understands its expansive hotel portfolio and business model as an owner and operator. Against this backdrop, it makes sense for CDL to fully consolidate its hotel subsidiary – if the right price can be agreed upon.

In our view, while the potential cash offer price is fairly attractive for CDL, it also offers M&C shareholders a valuable opportunity for liquidity at a sizeable 21.4% premium to the last closing price on 6 Oct.

Pending a formal offer, our fair value estimate of S$12.90 for CDL remains unchanged. Maintain BUY.

Momentum Singapore Stocks To Watch

  • DELONG
  • APAC REALTY
  • ROWSLEY
  • ASTI
  • GSS ENERGY

So Earn more With our Stock Recommendations

More Update: Stocks To Watch and hot stocks picks with Stock trading tips or Share Market Tips

 
Leave a comment

Posted by on October 11, 2017 in Stocks

 

Tags: , , , , , , , , , , , , ,

Singapore Stock Rowsley Limited update

Rowsley Limited Set To Become One Of Raffles Medical Group Ltd’s Competitors Soon
.
Singapore Stock Rowsley Limited (SGX: A50), a real estate company with businesses in design and engineering, real estate development and hospitality, made public that it plans to set foot into the healthcare sector.

This will be done by purchasing a 100% stake of Thomson Medical Pte Ltd and a 70.36% stake of TMC Life Sciences Berhad (0101.KL), a company listed in Malaysia. These assets are currently owned by the billionaire, Peter Lim. As at 16 March 2017, he owned close to 46% of Rowsley.

The proposed acquisition, which is valued at up to S$1.9 billion, is going to be an all-share deal and will be financed through the issuance of new shares of Rowsley at S$0.075 per share. This translates to a creation of 25.3 billion new shares. A Sales and Purchase Agreement is expected to be completed within two months.

Rowsley added that the “proposed acquisition will also bring TMCLS’s proposed Thomson Iskandar project in Iskandar, Johor, together with Rowsley’s investment in Vantage Bay Healthcare City”. Thomson Iskandar is an integrated development that comprises of a general hospital, medical suites, and a retail mall.

Mr. Ng Ser Miang, Rowsley’s Chairman said:

This proposed acquisition is an opportunity for us to acquire controlling stakes in two established healthcare assets in Singapore and Malaysia and be part of an expanding business. Healthcare is a big and growing market due to aging demographics, longer lifespan, major trends to increase birth rates, and growing affluence. This deal will diversify Rowsley’s portfolio as well as strengthen our current businesses. It will also significantly increase Rowsley’s market capitalization, market profile, and generate investor interest.

Upon completion of the deal, the firm plans to issue two bonus warrants for every one existing share owned by a shareholder and an additional warrant (known as a piggyback warrant) for every bonus warrant that is exercised. Each bonus warrant will have an exercise price of S$0.09 per share while each piggyback warrant will have an exercise price of S$0.12 per share.

Singapore Stock Market watchers will remember that back in 2010, Mr. Lim privatized Thomson Medical Centre, which was a listed company here, for S$513 million. Seven years later, the medical practice is going to return to the market. Rowsley said that it “may also consider changing its name to incorporate the word “Thomson” after completion” of the deal.

Currently, Rowsley’s outstanding shares is 4.74 billion. With a current price of S$0.117, the market capitalization is S$554.4 million. As a comparison, the largest private medical group practice in Singapore, Raffles Medical Group Ltd. (SGX: BSL), has a market cap of S$2.28 billion.

 
Leave a comment

Posted by on October 10, 2017 in Stocks

 

Singapore Stock City Developments Limited Update

CDL announced that they have reached an agreement with the independent directors of Millennium & Copthorne Hotels PLC (M&C) on the price at which these independent directors will recommend a possible cash offer to be made by CDL for all the outstanding ordinary shares in M&C that CDL does not already own. As at 9 Oct 2017, CDL indirectly owns 65.2% of the shares of M&C.

Singapore Stock City Developments Limited Update  www.mmfsolutions.sg

The proposed cash consideration comprises of a cash amount of 545 pence per M&C share and a special dividend of 7.5 pence per share which will be payable upon the offer becoming unconditional. This represents a 22.0% premium to the VWAP of 452.7 pence per share over the period of one month before 6 Oct 2017.

We highlight that there is no certainty a formal offer will be made, and discussions on the other terms and conditions of the proposed offer are still ongoing. We see this as a positive development for CDL given the attractive price of the proposed offer and believe a full consolidation of M&C on these terms will be accretive for the group.

Read More- OCBC kept at ‘buy’ on steady earnings growth in 3Q

Maintain BUY with an unchanged fair value estimate of S$12.90.

Singapore Stocks To Watch

  • FALCON ENERGY
  • TAT HONG
  • JAPFA
  • CHINA AVIATION
  • FRENCKEN

So Earn more With our Stock Recommendations

Recent Stock Recommendations

SGX:Buy FALCON ENERGY || Level 0.087|| Cut Profit @ 0.092 || Return 5.75%

KLSE:Buy PALETTE || Level 0.355 || Cut Profit @ 0.400 || Return 12.68%

More Update: Stocks To Watch and hot stocks picks with Stock trading tips or Share Market Tips

 
Leave a comment

Posted by on October 10, 2017 in Stocks

 

Tags: , , , , , , , , , , , , ,

Singapore Market Reviews of Singapore Post, Lazada & CapitaLand

Singapore Post said on Monday it was finalizing details with Southeast Asian e-commerce player Lazada, majority owned by China’s Alibaba Group Holding, and Singaporean property developer CapitaLand to bring “click and collect” services to the postal company’s redeveloped shopping mall, ahead of its official opening on Oct. 12.

We are working closely with CapitaLand and Lazada to finalize the details for a ‘click and collect’ service at this mall,” said Paul Coutts, group chief executive of SingPost, on Monday at an opening event for the company’s general post office in the shopping complex.

Read More- Which Singapore Stocks are Trending of This Week? 

Although the details are yet to be finalized, the tie-up will bring the convenience of online shopping to brick-and-mortar stores. Leveraging on SingPost’s e-commerce logistics capabilities, the partnership will likely include a collection service for online purchases and a home delivery service for items bought at the mall.

The general post office offers postal services including a POPStation, SingPost’s automated parcel lockers where packages including e-commerce purchases can be collected, sent and returned. The new POPStation at SingPost Centre will have 143 lockers, making it the largest in the city-state.

At a construction cost of 150 million Singapore dollars ($111 million), the redevelopment of the mall is a part of SingPost’s efforts to ensure stable rent income as conventional malls are squeezed by online retailers. By expanding its e-commerce logistics capabilities to brick-and-mortar stores, SingPost hopes to attract new customers and retailers. The 25,000 sq. meter-complex had an 80.4% rate of committed occupancy as of end-September.

“The SingPost Centre underscores SingPost’s transformation for a future where technology is changing how people shop, dine and play,” said Mervyn Lim, deputy group chief executive of corporate services at SingPost.

Read More- Go-To Resources About Intraday Trading Signals

Besides the post office, the mall houses a number of shops that showcase new technology, such as virtual reality and dedicated smartphone apps, to bring added convenience to customers.

Singaporean supermarket chain NTUC FairPrice is introducing its SCAN2GO service at its new outlet in SingPost Centre. Registered customers can pick up a hand scanner when they start shopping, and scan items as they browse the store. Calling the new outlet a “living lab“, FairPrice aims to introduce a number of new digital initiatives at the outlet

The supermarket chain has also launched a dedicated app called “FairPrice @ SingPost“, which navigates customers to specific shelves inside the store according to their shopping lists, eliminating the hassle of searching for items. The app uses cloud-based big data to send user-specific promotions through the app. Online purchases can be collected at refrigerated “Click&Collect” lockers inside the store. The store will also offer an ‘experiential corner’ with a VR device where product manufacturers and others can showcase their products and provide an immersive experience for customers.

 
Leave a comment

Posted by on October 9, 2017 in Stocks